LAVA Therapeutics NV
NASDAQ:LVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LAVA Therapeutics NV
Capital Expenditures
LAVA Therapeutics NV
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Capital Expenditures
-$23k
|
CAGR 3-Years
69%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Capital Expenditures
-$755k
|
CAGR 3-Years
27%
|
CAGR 5-Years
45%
|
CAGR 10-Years
2%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Capital Expenditures
-€1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Capital Expenditures
-$439k
|
CAGR 3-Years
71%
|
CAGR 5-Years
46%
|
CAGR 10-Years
25%
|
|
|
argenx SE
XBRU:ARGX
|
Capital Expenditures
-$95m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-79%
|
CAGR 10-Years
-77%
|
|
|
Merus NV
NASDAQ:MRUS
|
Capital Expenditures
-$610k
|
CAGR 3-Years
53%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-26%
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's Capital Expenditures?
Capital Expenditures
-23k
USD
Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Capital Expenditures amounts to -23k USD.
What is LAVA Therapeutics NV's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
50%
Over the last year, the Capital Expenditures growth was 97%. The average annual Capital Expenditures growth rates for LAVA Therapeutics NV have been 69% over the past three years , 50% over the past five years .
